Proteomic identification of potential markers of myosteatosis in human urine

Husi,Holger; MacDonald,Alisdair; Skipworth,Richard J.E.; Miller,Janice; Cronshaw,Andrew; Fearon,Kenneth C.H.; Ross,James A.

doi:10.3892/br.2018.1091

Proteomic identification of potential markers of myosteatosis in human urine

Authors:
- Holger Husi
- Alisdair MacDonald
- Richard J.E. Skipworth
- Janice Miller
- Andrew Cronshaw
- Kenneth C.H. Fearon
- James A. Ross
View Affiliations

Affiliations: Department of Diabetes and Cardiovascular Science, University of the Highlands and Islands, Centre for Health Science, IV2 3JH Inverness, UK, Department of Clinical Sciences, University of Edinburgh, EH16 4SB Edinburgh, UK, School of Biological Sciences, University of Edinburgh, Edinburgh, UK
Published online on: April 25, 2018 https://doi.org/10.3892/br.2018.1091
Pages: 557-564

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Myosteatosis, the infiltration of fat in skeletal muscle, is associated with lower skeletal muscle density (SMD) as detected by computed tomography (CT). It increases with aging and obesity and is thought to play a role in the aetiology of insulin resistance and type II diabetes. The clinical significance of myosteatosis in cancer cachexia, however, remains to be determined. Along with demonstrable subcutaneous and visceral lipolysis, myosteatosis may also be a key component of the syndrome. We aimed to investigate the use of human urine as a non‑invasive way to screen for molecular biomarkers of myosteatosis/reduced SMD using SELDI‑TOF mass spectrometry. Pre‑operative CT scans of patients undergoing surgery for upper gastrointestinal or hepatopancreaticobiliary cancer were analysed at the level of the third lumbar vertebrae. Myosteatosis was inferred as the presence of reduced SMD, which was defined as Hounsfield units for skeletal muscle <39.5 (two standard deviations below a normal healthy cohort). Urine was analysed by mass spectrometry using CM10 and IMAC30 SELDI‑chips. Peaks observed in the CM10 and IMAC30 chip types, showed marked expressional differences between control and myosteatosis, were further investigated by mascot SELDI matrix matching. A total of 55 patients was recruited; 31 patients were found to be myosteatotic on CT scan. Application of the IMAC30‑derived model to the entire cohort showed a sensitivity of 97%, specificity of 71% and an overall correctness of 85%. Application of the CM10 chipset‑based model to the entire cohort, showed a 77% sensitivity, 67% specificity and 73% overall correctness. Analysis of the peaks of interest resulted in the identification of significant fragments of cathepsin C, argin, arylsulfatase A and glial fibrillary acidic protein. We identified several potential urinary molecular biomarkers associated with reduced SMD in cancer. Such markers are potentially useful in deriving a clinical screening test for myosteatosis.

View Figures

View References

1	Delmonico MJ, Harris TB, Visser M, Park SW, Conroy MB, Velasquez-Mieyer P, Boudreau R, Manini TM, Nevitt M, Newman AB and Goodpaster BH: Health, Aging, and Body: Longitudinal study of muscle strength, quality, and adipose tissue infiltration. Am J Clin Nutr. 90:1579–1585. 2009. View Article : Google Scholar : PubMed/NCBI
2	Li Y, Xu S, Zhang X, Yi Z and Cichello S: Skeletal intramyocellular lipid metabolism and insulin resistance. Biophys Rev. 1:90–98. 2015.
3	Skipworth RJE, Stewart GD, Dejong CHC, Preston T and Fearon KCH: Pathophysiology of cancer cachexia: Much more than host-tumour interaction? Clin Nutr. 26:667–676. 2007. View Article : Google Scholar : PubMed/NCBI
4	Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, Cohen MH, Douglass HO Jr, Engstrom PF, Ezdinli EZ, et al: Eastern Cooperative Oncology Group: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med. 69:491–497. 1980. View Article : Google Scholar : PubMed/NCBI
5	Fearon KCH, Voss AC and Hustead DS: Cancer Cachexia Study Group: Definition of cancer cachexia: Effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr. 83:1345–1350. 2006. View Article : Google Scholar : PubMed/NCBI
6	Lieffers JR, Bathe OF, Fassbender K, Winget M and Baracos VE: Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery. Br J Cancer. 107:931–936. 2012. View Article : Google Scholar : PubMed/NCBI
7	Ding Q, Mracek T, Gonzalez-Muniesa P, Kos K, Wilding J, Trayhurn P and Bing C: Identification of macrophage inhibitory cytokine-1 in adipose tissue and its secretion as an adipokine by human adipocytes. Endocrinology. 150:1688–1696. 2009. View Article : Google Scholar : PubMed/NCBI
8	Russell ST and Tisdale MJ: The role of glucocorticoids in the induction of zinc-alpha2-glycoprotein expression in adipose tissue in cancer cachexia. Br J Cancer. 92:876–881. 2005. View Article : Google Scholar : PubMed/NCBI
9	Mracek T, Stephens NA, Gao D, Bao Y, Ross JA, Rydén M, Arner P, Trayhurn P, Fearon KC and Bing C: Enhanced ZAG production by subcutaneous adipose tissue is linked to weight loss in gastrointestinal cancer patients. Br J Cancer. 104:441–447. 2011. View Article : Google Scholar : PubMed/NCBI
10	Das SK, Eder S, Schauer S, Diwoky C, Temmel H, Guertl B, Gorkiewicz G, Tamilarasan KP, Kumari P, Trauner M, et al: Adipose triglyceride lipase contributes to cancer-associated cachexia. Science. 333:233–238. 2011. View Article : Google Scholar : PubMed/NCBI
11	Gray C, MacGillivray TJ, Eeley C, Stephens NA, Beggs I, Fearon KCH and Greig CA: Magnetic resonance imaging with k-means clustering objectively measures whole muscle volume compartments in sarcopenia/cancer cachexia. Clin Nutr. 30:106–111. 2011. View Article : Google Scholar : PubMed/NCBI
12	Stephens NA, Skipworth RJE, Macdonald AJ, Greig CA, Ross JA and Fearon KCH: Intramyocellular lipid droplets increase with progression of cachexia in cancer patients. J Cachexia Sarcopenia Muscle. 2:111–117. 2011. View Article : Google Scholar : PubMed/NCBI
13	Mueller TC, Bachmann J, Prokopchuk O, Friess H and Martignoni ME: Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia - can findings from animal models be translated to humans? BMC Cancer. 16:752016. View Article : Google Scholar : PubMed/NCBI
14	Fearon KCH and Baracos VE: Cachexia in pancreatic cancer: New treatment options and measures of success. HPB. 12:323–324. 2010. View Article : Google Scholar : PubMed/NCBI
15	Skipworth RJE, Stewart GD, Bhana M, Christie J, Sturgeon CM, Guttridge DC, Cronshaw AD, Fearon KCH and Ross JA: Mass spectrometric detection of candidate protein biomarkers of cancer cachexia in human urine. Int J Oncol. 36:973–982. 2010.PubMed/NCBI
16	Husi H, Stephens N, Cronshaw A, MacDonald A, Gallagher I, Greig C, Fearon KCH and Ross JA: Proteomic analysis of urinary upper gastrointestinal cancer markers. Proteomics Clin Appl. 5:289–299. 2011. View Article : Google Scholar : PubMed/NCBI
17	Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L and Baracos VE: Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: A population-based study. Lancet Oncol. 9:629–635. 2008. View Article : Google Scholar : PubMed/NCBI
18	Goodpaster BH, Thaete FL and Kelley DE: Composition of skeletal muscle evaluated with computed tomography. Ann N Y Acad Sci. 904:18–24. 2000. View Article : Google Scholar : PubMed/NCBI
19	Goodpaster BH, Carlson CL, Visser M, Kelley DE, Scherzinger A, Harris TB, Stamm E and Newman AB: Attenuation of skeletal muscle and strength in the elderly: The Health ABC Study. J Appl Physiol 1985. 90:2157–2165. 2001. View Article : Google Scholar : PubMed/NCBI
20	Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, Murphy R, Ghosh S, Sawyer MB and Baracos VE: Cancer cachexia in the age of obesity: Skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 31:1539–1547. 2013. View Article : Google Scholar : PubMed/NCBI
21	Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, et al: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 12:489–495. 2011. View Article : Google Scholar : PubMed/NCBI
22	Hosokawa M, Kashiwaya K, Eguchi H, Ohigashi H, Ishikawa O, Furihata M, Shinomura Y, Imai K, Nakamura Y and Nakagawa H: Over-expression of cysteine proteinase inhibitor cystatin 6 promotes pancreatic cancer growth. Cancer Sci. 99:1626–1632. 2008. View Article : Google Scholar : PubMed/NCBI
23	Dencker M, Tanha T, Karlsson MK, Wollmer P, Andersen LB and Thorsson O: Cystatin B, cathepsin L and D related to surrogate markers for cardiovascular disease in children. PLoS One. 12:e01874942017. View Article : Google Scholar : PubMed/NCBI
24	Farges MC, Balcerzak D, Fisher BD, Attaix D, Béchet D, Ferrara M and Baracos VE: Increased muscle proteolysis after local trauma mainly reflects macrophage-associated lysosomal proteolysis. Am J Physiol Endocrinol Metab. 282:E326–E335. 2002. View Article : Google Scholar : PubMed/NCBI
25	Stevenson EJ, Giresi PG, Koncarevic A and Kandarian SC: Global analysis of gene expression patterns during disuse atrophy in rat skeletal muscle. J Physiol. 551:33–48. 2003. View Article : Google Scholar : PubMed/NCBI
26	Salminen A and Kihlström M: Lysosomal changes in mouse skeletal muscle during the repair of exercise injuries. Muscle Nerve. 8:269–279. 1985. View Article : Google Scholar : PubMed/NCBI
27	Wen D, Corina K, Chow EP, Miller S, Janmey PA and Pepinsky RB: The plasma and cytoplasmic forms of human gelsolin differ in disulfide structure. Biochemistry. 35:9700–9709. 1996. View Article : Google Scholar : PubMed/NCBI
28	Rao J and Li N: Microfilament actin remodeling as a potential target for cancer drug development. Curr Cancer Drug Targets. 4:345–354. 2004. View Article : Google Scholar : PubMed/NCBI
29	Gao J, Qin Z, Guan X, Guo J, Wang H and Liu S: Overexpression of GSN could decrease inflammation and apoptosis in EAE and may enhance vitamin D therapy on EAE/MS. Sci Rep. 7:6042017. View Article : Google Scholar : PubMed/NCBI
30	Bentzinger CF, Barzaghi P, Lin S and Ruegg MA: Overexpression of mini-agrin in skeletal muscle increases muscle integrity and regenerative capacity in laminin-alpha2-deficient mice. FASEB J. 19:934–942. 2005. View Article : Google Scholar : PubMed/NCBI
31	Hettwer S, Dahinden P, Kucsera S, Farina C, Ahmed S, Fariello R, Drey M, Sieber CC and Vrijbloed JW: Elevated levels of a C-terminal agrin fragment identifies a new subset of sarcopenia patients. Exp Gerontol. 48:69–75. 2013. View Article : Google Scholar : PubMed/NCBI
32	Brenner M, Johnson AB, Boespflug-Tanguy O, Rodriguez D, Goldman JE and Messing A: Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease. Nat Genet. 27:117–120. 2001. View Article : Google Scholar : PubMed/NCBI
33	Scherbakov N, Knops M, Ebner N, Valentova M, Sandek A, Grittner U, Dahinden P, Hettwer S, Schefold JC, von Haehling S, et al: Evaluation of C-terminal agrin fragment as a marker of muscle wasting in patients after acute stroke during early rehabilitation. J Cachexia Sarcopenia Muscle. 7:60–67. 2016. View Article : Google Scholar : PubMed/NCBI
34	Watson CJ, Ledwidge MT, Phelan D, Collier P, Byrne JC, Dunn MJ, McDonald KM and Baugh JA: Proteomic analysis of coronary sinus serum reveals leucine-rich α2-glycoprotein as a novel biomarker of ventricular dysfunction and heart failure. Circ Heart Fail. 4:188–197. 2011. View Article : Google Scholar : PubMed/NCBI
35	Huzé C, Bauché S, Richard P, Chevessier F, Goillot E, Gaudon K, et al: Identification of an agrin mutation that causes congenital myasthenia and affects synapse function. Am J Hum Genet. 85:155–167. 2009. View Article : Google Scholar : PubMed/NCBI
36	Bentzinger CF, Barzaghi P, Lin S and Ruegg MA: Overexpression of mini-agrin in skeletal muscle increases muscle integrity and regenerative capacity in laminin-alpha2-deficient mice. FASEB J. 19:934–942. 2005. View Article : Google Scholar : PubMed/NCBI
37	Goodpaster BH, Kelley DE, Thaete FL, He J and Ross R: Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content. J Appl Physiol (1985). 89:104–110. 2000. View Article : Google Scholar : PubMed/NCBI
38	Ramage MI, Johns N, Deans CD, Ross JA, Preston T, Skipworth RJ, Jacobi C and Fearon KC: The relationship between muscle protein content and CT-derived muscle radio-density in patients with upper GI cancer. Clin Nutr. 37:752–754. 2018. View Article : Google Scholar : PubMed/NCBI